Definium Therapeutics, Inc. DFTX

Rank #2404 · Nasdaq · $4.0B market cap

Audited by KPMG LLP, no going-concern flag in the latest filing.

Score

20.5

P/E

-36.5

P/B

50.71

ROE

-139.1%

Op. Margin

–%

Debt Ratio

78%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -36.5x, P/B 50.71x. Ranks in the top 83% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -139.1%. Ranks in the top 96% of the universe.

Safety ★★★☆☆

Good

Debt ratio 78%. Ranks in the top 32% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2021	–	$-0.0B	$-0.0B	$0.0B	–	–
2022	–	$-0.1B	$-0.1B	$0.1B	–	16
2023	–	$-0.1B	$-0.1B	$0.2B	–	13
2024	–	$-0.1B	$-0.1B	$0.2B	–	31
2025	–	$-0.1B	$-0.1B	$0.1B	–	78